Institutions / Artia Global Partners LP

Artia Global Partners LP

CIK 1937964 · Institution · as of Dec 31, 2025
Portfolio value
$622.42M
Positions
50
As of
Dec 31, 2025

Top holdings

Dec 31, 2025View all 50 →
CompanyClassValueShares% of portfolio
Insmed Inc$118.73M682,21219.1%
Abivax SA$81.01M600,74713.0%
Argenx SE$54.41M64,6998.7%
ELI LILLY & Co$54.27M50,5008.7%
Viking Therapeutics Inc$25.31M719,3654.1%
Trevi Therapeutics, Inc.$25.21M2,013,6024.1%
Soleno Therapeutics, Inc.$24.71M533,6984.0%
ProShares Tr II$24.55M442,1193.9%
Uniqure NV$24.49M1,023,5393.9%
Newamsterdam Pharma Company$17.68M503,9362.8%
Astrazeneca PLC$17.54M190,7522.8%
Cidara Therapeutics Inc$15.64M70,8242.5%
EyePoint, Inc.$14.01M767,0982.3%
Ionis Pharmaceuticals Inc$11.42M144,3761.8%
Dianthus Therapeutics, Inc.$8.45M205,0901.4%
Revolution Medicines, Inc.$8.30M104,1901.3%
Quest Diagnostics Inc$7.08M40,8171.1%
Alnylam Pharmaceuticals Inc$6.92M17,4001.1%
Ventyx Biosciences, Inc.$6.28M695,9821.0%
Palvella Therapeutics, Inc.PVLACommon Stock$6.20M59,2001.0%
Mineralys Therapeutics IncMLYSCommon Stock$5.00M137,8000.8%
Sionna Therapeutics, Inc.$4.93M119,7410.8%
Palisade Bio, Inc.$4.68M1,992,3670.8%
Avidity Biosciences, Inc.$4.34M60,1000.7%
Scholar Rock Holding Corp$4.24M96,2850.7%

Activity

Dec 31, 2025
InsidersInstitutions
This fund's 13F position changes — what it's buying and selling.
No quarter-over-quarter changes yet — position changes appear once we've ingested two consecutive 13F filings for this manager. We currently hold 1 quarter of holdings.